Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CREDIBLE-CR trial of cefiderocol versus best available therapy for severe carbapenem-resistant Gram-negative infections
MOH_2017-03-26_000274Phase 3Recruiting
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cefiderocol in hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), Healthcare-associated pneumonia (HCAP) and 4 more (2 arms), sponsored by Shionogi & Co., Ltd. Started Jun 2016; status: recruiting.
02
Drugs
cefiderocol
03
Conditions
hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)Healthcare-associated pneumonia (HCAP)complicated urinary tract infection (cUTI)bloodstream infection (BSI)
Beyond the preview
Go deeper on MOH_2017-03-26_000274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-26_000274.